1. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427
2. Fayers PM, Ashby D, Parmar MK (1997) Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med 16(12):1413–1430
3. U.S. Food and Drug Administration, Amgen Inc. Amgen presentations: Cardiovascular Safety; Meeting of the bone reproductive and urologic drugs advisory committee. January 16, 2019. Accessed at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-16-2019-meeting-bone-reproductive-and-urologic-drugs-advisory-committee-meeting-announcement. Accessed Jan 2020
4. Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, Spiering W (2016) Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis. Atherosclerosis. 252:106–115
5. U.S. Food and Drug Administration. FDA Briefing information document: Meeting of the bone reproductive and urologic drugs advisory committee. January 16, 2019: page 35. Accessed at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-16-2019-meeting-bone-reproductive-and-urologic-drugs-advisory-committee-meeting-announcement. Accessed Jan 2020